Imaging agent developer ImaginAb signed a multiyear, nonexclusive license with Pfizer to supply the zirconium-89 (Zr-89) CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
Quantitative imaging of these cells identifies drug efficacy more quickly and has ramifications for clinical trials and bringing the agent to market, the firms said.
ImaginAb will supply clinical doses of Zr-89 CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials along with technical, clinical, and regulatory support. ImaginAb will receive license fees and payments for manufacturing and other support.
The agreement expands upon a precompetitive alliance between ImaginAb, Pfizer, and other global pharmaceutical companies that focused on the development of Zr-89 CD8 ImmunoPET.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
